The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Paclitaxel in cancer therapy
Abstract
The last decade witnessed the introduction of exciting new chemotherapeutic agents. Among these, paclitaxel emerged as one of the most powerful compounds. Paclitaxel promotes the polymerisation of tubulin, thereby causing cell death by disrupting the normal microtubule dynamics required for cell division and vital interphase processes. Mechanisms of acquired resistance to paclitaxel include alterations of tubulin structure and the amplification of membrane phosphoglycoproteins that function as drug-efflux pumps. Toxicities associated with paclitaxel include hypersensitivity reaction, neurotoxicity and haematological toxicities. Toxicities may be both dose- and schedule-dependent. Paclitaxel has activity against a broad band of tumour types, including breast, ovarian, lung, head and neck cancers. Paclitaxel also has activity in other malignancies that are refractory to conventional chemotherapy, including previously-treated lymphoma and small cell lung cancers and oesophageal, gastric endometrial, bladder and germ cell tumours. Paclitaxel is also active against AIDS-associated Kaposi's sarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 3×
“Patients on this study had a particularly poor prognosis related to overexpression of HER2, the progression of disease after adjuvant therapy that included an anthracycline and prior treatment with high-dose chemotherapy followed by haematopoietic stem-cell rescue (22%) [55].”
InfluentialBcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death
Oltval, Z. N., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)90509-o · Cited by 6,003
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,970
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.
Jordan, M. A., Toso, R. J., Thrower, D., & Wilson, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9552 · Cited by 1,095
Taxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
Piccart, M. J. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.699 · Cited by 981
Clinical toxicities encountered with paclitaxel (Taxol).
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Sg, A., & Rc, D. (1993) · PubMed · Cited by 692
Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.
Haldar, S., Chintapalli, J., & Croce, C. M. (1996) · PubMed · Cited by 651
Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E., Kerr, I., Vermorken, J. B., Buser, K., & Colombo, N. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2654 · Cited by 626
Taxol binds to polymerized tubulin in vitro
Parness, J., & Horwitz, S. (1981) · The Journal of Cell Biology · doi:10.1083/jcb.91.2.479 · Cited by 620
Muggia, F. M., Braly, P. S., Brady, M. F., Sutton, G., Niemann, T. H., Lentz, S. L., Alvarez, R. D., Kucera, P. R., & Small, J. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.106 · Cited by 601
Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., Jiroutek, M., & Johnson, D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.623 · Cited by 589
Dumontet, C., & Sikic, B. I. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.1061 · Cited by 574
Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A., & Martini, C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2688 · Cited by 553
Fossati, R., Confalonieri, C., Torri, V, Ghislandi, E., Penna, A., Pistotti, V, Tinazzi, A., & Liberati, A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3439 · Cited by 546
Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer
Fisher, B., Dignam, J., Emir, B., Bryant, J., DeCillis, A., Wolmark, N., Wickerham, D. L., Dimitrov, N. V., Abramson, N., Atkins, J. N., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.22.1673 · Cited by 521
Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer
Murphy, W. K., Fossella, F. V., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H., Raber, M. N., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.384 · Cited by 429
Cortes, J. E., & Pazdur, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2643 · Cited by 421
Taxol: Mechanisms of Action and Resistancea
HORWITZ, S. B., LOTHSTEIN, L., MANFREDI, J. J., MELLADO, W., PARNESS, J., ROY, S. N., SCHIFF, P. B., SORBARA, L., & ZEHEB, R. (1986) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1986.tb38455.x · Cited by 416
Taxol binds to cellular microtubules.
Manfredi, J. J., Parness, J., & Horwitz, S. B. (1982) · The Journal of cell biology · doi:10.1083/jcb.94.3.688 · Cited by 409
Taxol-induced polymerization of purified tubulin. Mechanism of action.
Kumar, N. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68639-4 · Cited by 401
Cardiac disturbances during the administration of taxol.
Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., & Donehower, R. C. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1704 · Cited by 395
Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death.
Blagosklonny, M. V., Giannakakou, P., El‐Deiry, W. S., Kingston, D. G. I., Higgs, P. I., Neckers, L. M., & Fojo, T. (1997) · PubMed · Cited by 382
The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review
Wang, L. G., Liu, X. M., Kreis, W., & Budman, D. R. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050989 · Cited by 373
Thigpen, J. T., Blessing, J. A., Ball, H., Hummel, S. J., & Barrett, R. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1748 · Cited by 372
Schiff, P. B., & Horwitz, S. B. (1981) · Biochemistry · doi:10.1021/bi00514a041 · Cited by 368
Chaudhry, V., Rowinsky, E. K., Sartorius, S. E., Donehower, R. C., & Cornblath, D. R. (1994) · Annals of Neurology · doi:10.1002/ana.410350310 · Cited by 363
Huizing, M. T., Keung, A. C., Rosing, H., van der Kuij, V, ten Bokkel Huinink, W. W., Mandjes, I. M., Dubbelman, A. C., Pinedo, H. M., & Beijnen, J. H. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2127 · Cited by 308
Paclitaxel Resistance in Non–Small-Cell Lung Cancer Associated With Beta-Tubulin Gene Mutations
Monzó, M., Rosell, R., Sánchez, J. J., Lee, J. S., O'Brate, A., González-Larriba, J. L., Alberola, V., Lorenzo, J. C., Núñez, L., Ro, J. Y., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1786 · Cited by 306
Chemotherapy vs Supportive Care in Advanced Non-Small-Cell Lung Cancer
Marino, P., Pampallona, S., Preatoni, A., Cantoni, A., & Invernizzi, F. (1994) · Chest · doi:10.1378/chest.106.3.861 · Cited by 299
Crivellari, D., Bonetti, M., Castiglione-Gertsch, M., Gelber, R. D., Rudenstam, C.-M., Thürlimann, B., Price, K. N., Coates, A. S., Hürny, C., Bernhard, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1412 · Cited by 291 · cited 1×
“In conclusion, this analysis shows that some months of chemotherapy result in absolute improvement in 10-year survival rates in 7 and 11% in women < 50 years with nodenegative or -positive tumours, respectively, 2 and 3% in nodenegative and -positive patients, for those aged 50 – 69 years [58-61].”
MethodFisher, B., Redmond, C., Legault-Poisson, S., Dimitrov, N. V., Brown, A. M., Wickerham, D. L., Wolmark, N., Margolese, R. G., Bowman, D., & Glass, A. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.6.1005 · Cited by 291
Gianni, L., Viganò, L., Locatelli, A., Capri, G., Giani, A., Tarenzi, E., & Bonadonna, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1906 · Cited by 278
Bhalla, K. N., Ibrado, A. M., Tourkina, E., Tang, C., Mahoney, M. E., & Huang, Y. (1993) · PubMed · Cited by 273
Einzig, A. I., Wiernik, P. H., Sasloff, J., Runowicz, C. D., & Goldberg, G. L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1748 · Cited by 263
The Taxoids: Comparative Clinical Pharmacology and Therapeutic Potential
Eisenhauer, E. A., & Vermorken, J. B. (1998) · Drugs · doi:10.2165/00003495-199855010-00002 · Cited by 248
Advanced Ovarian Cancer Trialists' Group, Aabo, K., Adams, M., Adnitt, P., Alberts, D., Athanazziou, A., Barley, V, Bell, D., Bianchi, U., Bolis, G., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.710 · Cited by 234
Scatena, C. D., Stewart, Z. A., Mays, D., Tang, L. J., Keefer, C. J., Leach, S. D., & Pietenpol, J. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30777 · Cited by 229
Rowinsky, E. K., Chaudhry, V., Cornblath, D. R., & Donehower, R. C. (1993) · PubMed · Cited by 208
A reassessment of cardiac toxicity associated with Taxol.
Arbuck, S. G., Strauss, W. H., Rowinsky, E. K., Christian, M. C., Suffness, M., Adams, J., Oakes, M., McGuire, W. P., Reed, E., & Gibbs, H. H. (1993) · PubMed · Cited by 195
Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Kohn, E. C., Sarosy, G., Bicher, A., Link, C., Christian, M., Steinberg, S. M., Rothenberg, M., Adamo, D. O., Davis, P., Ognibene, F. P., et al. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.1.18 · Cited by 187
Geels, P., Eisenhauer, E., Bezjak, A., Zee, B., & Day, A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2395 · Cited by 184
Bcl-xL is phosphorylated in malignant cells following microtubule disruption.
Poruchynsky, M. S., Wang, E. E., Rudin, C. M., Blagosklonny, M. V., & Fojo, T. (1998) · PubMed · Cited by 183
Woodcock, D. M., Jefferson, S., Linsenmeyer, M. E., Crowther, P. J., Chojnowski, G. M., Williams, B. T., & Bertoncello, I. (1990) · PubMed · Cited by 168
Crossin, K. L., & Carney, D. H. (1981) · Cell · doi:10.1016/0092-8674(81)90417-7 · Cited by 159
Perez, E. A. (1998) · The Oncologist · doi:10.1634/theoncologist.3-6-373 · Cited by 152
High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells.
Tang, C., Willingham, M. C., Reed, J. C., Miyashita, T., Ray, S. K., Ponnathpur, V., Huang, Y., Mahoney, M. E., Bullock, G., & Bhalla, K. N. (1994) · PubMed · Cited by 142
Webster, L. K., Linsenmeyer, M. E., Millward, M., Morton, C. G., Bishop, J. F., & Woodcock, D. M. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.20.1685 · Cited by 128
Hamel, E., del Campo, A. A., Lowe, M., & Lin, C. M. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68489-9 · Cited by 116
International Breast Cancer Study Group (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1385 · Cited by 113
Successful re-treatment with taxol after major hypersensitivity reactions.
Peereboom, D. M., Donehower, R. C., Eisenhauer, E. A., McGuire, W. P., Onetto-Pothier, N., Hubbard, J. L., Piccart, M. J., Gianni, L., & Rowinsky, E. K. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.5.885 · Cited by 111
Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly.
Cabral, F., Wible, L., Brenner, S., & Brinkley, B. R. (1983) · The Journal of Cell Biology · doi:10.1083/jcb.97.1.30 · Cited by 97
Optic Nerve Disturbances: a New Form of Paclitaxel Neurotoxicity
Capri, G., Munzone, E., Tarenzi, E., Fulfaro, F., Gianni, L., Caraceni, A. T., Martini, C., & Scaioli, V. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.14.1099 · Cited by 94
Burkhart, C. A., Berman, J. W., Swindell, C. S., & Horwitz, S. B. (1994) · PubMed · Cited by 91
Conte, P., Baldini, E., Gennari, A., Michelotti, A., Salvadori, B., Tibaldi, C., Danesi, R., Innocenti, F., Gentile, A., Dell'Anna, R., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2510 · Cited by 90
Wilson, L., Miller, H. P., Farrell, K., Snyder, K. B., Thompson, W. C., & Purich, D. L. (1985) · Biochemistry · doi:10.1021/bi00340a045 · Cited by 80
Liu, Q.-Y., & Stein, C. A. (1997) · PubMed · Cited by 70
Mechanisms of action and resistance to tubulin-binding agents
Dumontet, C. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.4.779 · Cited by 51
Cited by
Response of Plant Secondary Metabolites to Environmental Factors
Yang, L., Wen, K.-S., Ruan, X., Zhao, Y.-X., Wei, F., & Wang, Q. (2018) · Molecules · doi:10.3390/molecules23040762 · Cited by 1,726
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Martins, P., Jesus, J., Santos, S., Raposo, L., Roma-Rodrigues, C., Baptista, P., & Fernandes, A. (2015) · Molecules · doi:10.3390/molecules200916852 · Cited by 716
Hyaluronic acid for anticancer drug and nucleic acid delivery
Dosio, F., Arpicco, S., Stella, B., & Fattal, E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.011 · Cited by 596
Supramolecular cancer nanotheranostics
Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411
Metadata
- Authors
- Markman, M., & Mekhail, T. M.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2002-06
- Volume
- 3
- Issue
- 6
- Pages
- 755-766
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2153138245
- Cited by
- 375
- References
- 70
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.